Landmark Lawsuit Filed Against SEC to Protect Future Whistleblowers

May 30, 2019

Donald A. Milne III, Instaprin Pharmaceuticals, Inc.

Offering Fraud


Defendants: Instaprin Pharmaceuticals, Inc.
Donald A. Milne III

Defendants consented to entry of the judgment including this combined sanction, in an enforcement action where the SEC alleged that they defrauded numerous (including many elderly) investors. Investors were allegedly told their money would be used for the operating expenses of Instaprin Pharmaceuticals, which was purportedly developing a revolutionary fast acting aspirin to instantly stop heart attacks and strokes, whereas Milne instead used it largely for personal expenses.

Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR
Thank you for submitting some email to us.